NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Distribution · USD

Cosmos Health Inc. (COSM) Stock Analysis

Cosmos Health Inc. (COSM) is a Medical Distribution stock listed on NASDAQ and quoted in US Dollar.

COSM

$0.27

+$0.01 (+2.63%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COSM with… →

COSM Key Statistics

As of Sep 4, 2026
Trading
Open
$0.27
Previous Close
$0.27
Day's Range
0.26–0.28
52-Week Range
0.16–1.32
Volume
2.17M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
4.17
Valuation
Market Cap
$27.49M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
3.90
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.37
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.67
Financials (FY)
Revenue (FY)
$65.27M+19.93%
Net Income (FY)
−$19.14M
Profit marginThe share of revenue left as profit after all costs and taxes.
−33.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
100.63M
1-Year Return
−57.14%
Dividend and dates
Avg Volume
10.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

COSM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−45.18%
2025−25.56%
2024−52.55%
2023−69.08%
2022+35.31%
2021−33.92%
2020+131.82%
2019−45.00%
2018−60.78%
2017+24.39%
2016 (partial year)+17.14%

As of September 4, 2026.

COSM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$65.27M−$19.14M−29.3%
2024$54.43M−$16.18M−29.7%
2023$53.38M−$18.54M−34.7%
2022$50.35M−$13.83M−27.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$65.27M$7.90M−$16.54M−$19.14M−29.3%
2024$54.43M$4.31M−$15.25M−$16.18M−29.7%
2023$53.38M$4.35M−$21.83M−$18.54M−34.7%
2022$50.35M$5.96M−$7.47M−$13.83M−27.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

COSM Valuation vs Medical Distribution Median

Median of 13 stocks
MetricCOSMMedical Distribution medianvs median
P/S ratio0.370.363% above
Profit margin−33.08%−4.03%29.1 pts below

Medians across 13 Medical Distribution stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cosmos Health Inc. (COSM) carries a market capitalisation of $27.49M. The company sits in the Healthcare sector, in the Medical Distribution industry. The company reports 163 employees.

Over the past 52 weeks the price has ranged from $0.16 to $1.32. COSM last closed at $0.27 on September 4, 2026. That is +$0.01 (+2.63%) against the previous close. The latest close sits 68.52% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $65.27M. That is +19.93% against the prior fiscal year, when revenue was $54.43M. The same year closed with a net loss of $19.14M. The reported profit margin is −33.08%. That is 29.1 percentage points below the Medical Distribution median of −4.03%. Trailing earnings per share are −0.67.

Across the 4 fiscal years on file, revenue moves from $50.35M in 2022 to $65.27M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 3.9. The price-to-sales ratio is 0.37. On price-to-sales that is 3.23% above the Medical Distribution median of 0.36. The medians here are taken across 13 Medical Distribution companies that report the metric.

The reported beta is 4.17. Annualized volatility over the trailing 10 years is 2,180.19%. Over the trailing twelve months the price has returned −57.14%. Across 10 years the annualized return works out at −27.17%.

Growth & Income

The record shows no dividend for COSM.

Across the complete calendar years on file, 2020 returned +131.82% and 2023 returned −69.08%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −45.18% year to date.

Peer Comparison

Cosmos Health Inc. (COSM) operates in the Medical Distribution industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cosmos Health Inc. COSM $27.49M —
McKesson Corporation MCK $105.86B 24.7
Cencora, Inc. COR $63.15B 25.1
Cardinal Health, Inc. CAH $57.49B 34.4

The Medical Distribution industry average P/E ratio is 25.8x. Cosmos Health Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Distribution Stocks

MCK

McKesson Corporation

$105.86B

 COR

Cencora, Inc.

$63.15B

 CAH

Cardinal Health, Inc.

$57.49B

 HSIC

Henry Schein, Inc.

$10.01B

 AHG

Akso Health Group

$726.49M

 FOCL

EDAP TMS S.A.

$190.70M
View all Medical Distribution stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cosmos Health Inc.

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.

Visit website →